EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.

Cancer Res 2016 Mar 29;76(6):1591-602. Epub 2016 Jan 29.

Genomics Institute of the Novartis Research Foundation, San Diego, California.

Non-small cell lung cancer patients carrying oncogenic EGFR mutations initially respond to EGFR-targeted therapy, but later elicit minimal response due to dose-limiting toxicities and acquired resistance. EGF816 is a novel, irreversible mutant-selective EGFR inhibitor that specifically targets EGFR-activating mutations arising de novo and upon resistance acquisition, while sparing wild-type (WT) EGFR. EGF816 potently inhibited the most common EGFR mutations L858R, Ex19del, and T790M in vitro, which translated into strong tumor regressions in vivo in several patient-derived xenograft models. Notably, EGF816 also demonstrated antitumor activity in an exon 20 insertion mutant model. At levels above efficacious doses, EGF816 treatment led to minimal inhibition of WT EGFR and was well tolerated. In single-dose studies, EGF816 provided sustained inhibition of EGFR phosphorylation, consistent with its ability for irreversible binding. Furthermore, combined treatment with EGF816 and INC280, a cMET inhibitor, resulted in durable antitumor efficacy in a xenograft model that initially developed resistance to first-generation EGFR inhibitors via cMET activation. Thus, we report the first preclinical characterization of EGF816 and provide the groundwork for its current evaluation in phase I/II clinical trials in patients harboring EGFR mutations, including T790M.

Download full-text PDF

Source
http://cancerres.aacrjournals.org/content/early/2016/01/29/0
Web Search
http://cancerres.aacrjournals.org/content/76/6/1591.full.pdf
Web Search
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-15-2581DOI Listing
March 2016
104 Reads
9.329 Impact Factor

Publication Analysis

Top Keywords

egfr mutations
12
non-small cell
8
egfr
8
lung cancer
8
egf816
8
cell lung
8
inhibition egfr
8
mutations
5
levels efficacious
4
efficacious doses
4
doses egf816
4
egf816 treatment
4
model levels
4
exon insertion
4
insertion mutant
4
mutant model
4
provided sustained
4
treatment led
4
single-dose studies
4
tolerated single-dose
4

Similar Publications